Skip to content

Study · Animal study (in vivo) · cat · 1985

3 results

Comparative effects of vasoactive intestinal peptide and secretin on exocrine pancreatic secretion in the cat.

Roche C, Vagne M, Scarpignato C, Mutt V

Regulatory peptides1 Oct 1985Cited by 2 (Europe PMC)

PMID2999882 (opens in a new tab)DOI10.1016/0167-0115(85)90193-4 (opens in a new tab)PepBankPUB-02999882
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In anaesthetized cats, bolus intravenous VIP stimulated exocrine pancreatic secretion only weakly, compared with secretin.

    In plain wordsIn anaesthetized cats, a single VIP injection into a vein stimulated the pancreas only weakly compared with secretin.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePancreatic secretion after bolus intravenous VIP
    Study

    catn: not reported in source

    Comparator
    Secretin
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated · intravenous bolus injectionAs given in this study (cat).

    Source sentences

    Summary
    After bolus injection, VIP stimulated pancreatic secretion only weakly.
    1 context sentence
    Summary · context
    The stimulatory effect of vasoactive intestinal peptide (VIP) and secretin has been compared on exocrine pancreatic secretion in anaesthetized cats. Both peptides were given by bolus intravenous injection and continuous intravenous infusion.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In anaesthetized cats, the maximal effect of VIP on pancreatic secretion during intravenous infusion did not differ significantly from that of secretin.

    In plain wordsIn anaesthetized cats, VIP given by drip into a vein reached the same maximum pancreatic effect as secretin.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeMaximal pancreatic secretion during intravenous VIP infusion
    Study

    catn: not reported in source

    Comparator
    Secretin
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated · continuous intravenous infusionAs given in this study (cat).

    Source sentences

    Summary
    On the contrary, during intravenous infusion, the maximal effect of VIP did not differ significantly from that of secretin.
    1 context sentence
    Summary · context
    The stimulatory effect of vasoactive intestinal peptide (VIP) and secretin has been compared on exocrine pancreatic secretion in anaesthetized cats. Both peptides were given by bolus intravenous injection and continuous intravenous infusion.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In anaesthetized cats, the potency of VIP on exocrine pancreatic secretion was always lower than that of secretin.

    In plain wordsIn anaesthetized cats, VIP was always less potent than secretin in stimulating the pancreas.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePotency of VIP versus secretin on pancreatic secretion
    Study

    catn: not reported in source

    Comparator
    Secretin
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    while the potency of VIP is always lower than that of secretin
    1 context sentence
    Summary · context
    The stimulatory effect of vasoactive intestinal peptide (VIP) and secretin has been compared on exocrine pancreatic secretion in anaesthetized cats. Both peptides were given by bolus intravenous injection and continuous intravenous infusion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.